TabletsClinical Overview
Moxifloxacin is a fourth-generation fluoroquinolone antibiotic with enhanced bactericidal activity against Gram-positive bacteria (including penicillin-resistant Streptococcus pneumoniae) and anaerobes, alongside standard Gram-negative coverage. It does not require dosage adjustments in renal impairment because it is eliminated primarily by hepatic glucuronide and sulfate conjugation. Indicated for community-acquired pneumonia, acute bacterial sinusitis, complicated intra-abdominal infections, and second-line MDR-TB regimens.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily with a glass of water, with or without food. Do not chew or crush. Maintain separation of at least 4 hours before or 2 hours after antacids containing aluminum/magnesium, iron supplements, and multivitamins. Finish the full treatment course.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nausea, diarrhea, dizziness, headache, vomiting. Rare/Severe: QT prolongation and torsades de pointes, tendonitis/tendon rupture, peripheral neuropathy, acute liver failure, and Clostridioides difficile colitis.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in patients with known QT prolongation, uncorrected hypokalemia, or severe hepatic impairment (Child-Pugh C). Boxed warning for tendonitis and neurotoxicity. Avoid co-administration with antiarrhythmic drugs (amiodarone, sotalol) and other QT-prolonging medicines.
Schedule H1 (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Moxifloxacin Hydrochloride Eye Drops 0.5% w/v
Moxifloxacin Hydrochloride (0.5% w/v ophthalmic solution) is a fourth-generation fluoroquinolone broad-spectrum bactericidal eye drop on the WHO Model List of Essential Medicines. It simultaneously inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, demonstrating high corneal tissue penetration, low resistance rates, and exceptional potency against Streptococcus pneumoniae, Staphylococcus aureus (including MRSA), and Gram-negative ocular pathogens. Self-preserved formulation eliminates the need for epithelial-toxic preservatives like benzalkonium chloride. Indicated for bacterial conjunctivitis and peri-operative prophylaxis in intraocular surgeries.
Bromfenac 0.09% w/v + Moxifloxacin 0.5% w/v Eye Drops
Moxifloxacin and NSAID (Bromfenac 0.09% or Ketorolac 0.5%) ophthalmic solution is an antibacterial and non-steroidal anti-inflammatory combination. Moxifloxacin provides broad bactericidal coverage, while the ophthalmic NSAID inhibits cyclooxygenase (COX-1/COX-2) enzymes to block prostaglandin synthesis, relieving ocular pain, photophobia, and anterior chamber flare without the intraocular pressure spikes or cataract risks associated with steroids. Indicated for post-cataract surgery ocular pain, inflammation, and infection prophylaxis.
Moxifloxacin 0.5% w/v + Dexamethasone 0.1% w/v Eye Drops
Moxifloxacin and Corticosteroid (Dexamethasone 0.1% or Prednisolone 1%) ophthalmic drops is a broad-spectrum anti-infective and potent anti-inflammatory combination. Moxifloxacin (0.5%), a 4th-generation fluoroquinolone, inhibits bacterial DNA gyrase and topoisomerase IV across Gram-positive, Gram-negative, and atypical pathogens, while the steroid suppresses ocular surgical trauma, anterior chamber inflammation, and corneal edema. Indicated for post-operative prevention and treatment of inflammation and infection following cataract, refractive, or vitreoretinal surgery.
Moxifloxacin 400mg + Cefixime 400mg Tablet
Cefixime and Moxifloxacin combination pairs a 3rd-generation oral cephalosporin with a respiratory fluoroquinolone. Provides enhanced dual coverage against typical and atypical respiratory pathogens, resistant Gram-negative bacilli, and anaerobes. Indicated for severe or refractory community-acquired pneumonia, acute exacerbations of chronic bronchitis, and complicated polymicrobial infections.